Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citation
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
Items 701–789 of 789
A nátrium-glükóz-kotranszporter-2-gátlók a diabetes mellitus kezelésén túl
Szekeres, Z. J., Stolcz, T., & Szabados, E. (2020) · Cardiologia Hungarica · doi:10.26430/chungarica.2020.50.5.372 · Cited by 2
Miya, A., Nakamura, A., Cho, K. Y., Kawata, S., Nomoto, H., Nagai, S., Sugawara, H., Taneda, S., Tsuchida, K., Omori, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13479 · Cited by 1
A PARADIGM SHIFT FOR THE SGLT2 INHIBITORS – TREATING THE HEART WITH ANTI-HYPERGLYCAEMIC DRUGS
Bădilă, E. (2021) · FARMACIA · doi:10.31925/farmacia.2021.5.2 · Cited by 1
“Moreover, SGLT2i leave the metabolic counter-regulation intact, increasing hepatic gluconeogenesis and plasma glucagon levels [28].”
Isotopic Tracers for the Measurement of Metabolic Flux Rates
Beysen, C., Angel, T. E., Hellerstein, M. K., & Turner, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_9 · Cited by 2
Metabolic effects of empagliflozine
Кедик, А. В., & Kutsin, O. O. (2022) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2022-5-04 · Cited by 3
A translational viewpoint explaining its potential salutary effects
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw015 · Cited by 1
Glucagon in Islet and Metabolic Regulation
Sandoval, D. A., Tong, J., & Alessio, D. D. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch7 · Cited by 1
Radellini, S., Vigneri, E., Guarnotta, V., Pantò, F., & Giordano, C. S. D. S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01119-6 · Cited by 1
Dagogo-Jack, S. E. (2023) · JAMA · doi:10.1001/jama.2023.9964 · Cited by 1
Is there any progress in the blood glucose lowering therapy of type 2 diabetes?
Winkler, G. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29979
Prié, D. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30051-1
Les inhibiteurs de SGLT2 : pour quels patients ? Quelle place dans la stratégie thérapeutique ?
Guerci, B. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30057-2
Orale Antidiabetika ermöglichen eine individualisierte Therapie
Müller‐Wieland, D. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-2719-9
Stümvoll, M., & Scherbaum, W. A. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1344-7
Faustino, B. D. S., Costa, A. D. R., Bortolon, L. N. M., de Sá, L. B. P. C., Rocha, D. R. T. W., & Arbex, A. K. (2016) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2016.61012
The effects of hyperglycemia on glucose metabolism in epithelial ovarian cancer
Kellenberger, L. D. (2016) · The Atrium (University of Guelph)
8. Progress in Treatment of Diabetes
Kaku, K. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.117b
Clinic al Implic a tions of Ba s ic R e se ar ch
Hattersley, A. T., & Thorens, B. (2015)
Fukazawa, M., Nagata, T., Suzuki, M., Suzuki, Y., & Kawabe, Y. (2016) · Folia Pharmacologica Japonica · doi:10.1254/fpj.148.259
Krentz, A. J., & Sinclair, A. J. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch21
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_19-1
Self-citationGestione terapeutica del diabete di tipo 2
Rigalleau, V., Cherifi, B. G., Blanco, L., Alexandre, L., & Mohammedi, K. (2018) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(18)90444-4
SGLT2 Inhibitors: Mechanism of Action, Pros, and Cons
Hackethal, V. (2014)
Prise en charge thérapeutique du diabète de type 2
Rigalleau, V., Cherifi, B., Blanco, L., Alexandre, L., & Mohammedi, K. (2017) · Time to knit · doi:10.1016/s1634-6939(17)69798-9 · Cited by 2
8. Progress in Treatment of Diabetes
Kaku, K. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.2275
Liraglutide and Dulaglutide Have Comparable HbA1c Reduction in Emirati Patients with T2DM
Nada, A. M., & Younan, M. A. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.114008
“= (HbA1c/Hb) × 91.5 + 2.15 [27].”
InfluentialAso, Y., Iijima, T., Hosonuma, S., Kurai, H., Kanitani, H., Sakurai, S., Tomaru, T., Jojima, T., & Usui, I. (2021) · doi:10.22541/au.162260353.34823381/v1
Takeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3918294
Okura, T., Fujioka, Y., Nakamura, R., Kitao, S., Ito, Y., Anno, M., Matsumoto, K., Shoji, K., Matsuzawa, K., Izawa, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-882630/v1
Sedykh, D. Y., Кашталап, В. В., & Барбараш, О. Л. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-29-8-12
Evolution in Understanding of Cardiovascular Outcomes in Diabetes
Maheshwari, A. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115030
Around Australia – Chickens and Campylobacter
Templeton, J. M., Hewitson, J. M., Giffard, P. M., & Blackall, P. J. (2014)
Cortés, A. M. T. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/178231
Alsahli, M., Shrayyef, M. Z., & Gerich, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_2-2 · Cited by 2
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_19
Self-citationYoo, J. H., & Kim, J. H. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_13
Aschner, P. J. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727299606.793538292
SGLT2 inhibitors: suggestions from the amphibian world
Michelassi, S. (2022) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2022.2423
Einfluss von Dapagliflozin auf die endogene Glukoseproduktion bei Typ-2-Diabetes
Jecht, M. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00942-0
Improving flexibility in substrate metabolism: a pharmacological and lifestyle approach
Veelen, A. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20230125av
Effect of Dapagliflozin on Visceral Fat Index in Overweight Type 2 Diabetes Patients
毕, 佳. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131064
SGLT2 Inhibitors for Nephrologists
Mahmood, M. B. U. R., & Farishta, S. (2022) · EMJ Nephrology · doi:10.33590/emjnephrol/22-00083
代, 琳. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132386
Quiz intensiv – stellen Sie die Diagnose!
Uhlig, M., & Karasimos, E. (2023) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-1888-6512
A metabolically healthy lifestyle: A matter of timing?
Andriessen, C. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230706ca
Prevalence of Sarcopenia in Insulin Treated Older Adults with Type 2 DiabetesPreprint
Leite, S. A. O., Bastos, M., da Silva, M. P., Lavalle, A. C. R., Bertogy, M. C. V., Kuklik, S. C. V., & Umpierrez, G. E. (2023) · Research Square · doi:10.21203/rs.3.rs-3216192/v1
Glucagon in Islet and Metabolic Regulation
Campbell, J. E., & D’Alessio, D. A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch8
Virtual Screening of Iridoids SGLT2 Inhibitors Based on Molecular Docking and Pharmacophore Model
Zhang, D., Xin, T., Xu, X., Wang, Y., Shi, M., Liu, Y., Ma, R., & Xue, H. (2023) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm58861.2023.10385277
Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research
夏, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142429
Ishimaru, Y., Kessoku, T., Nonaka, M., Kitajima, Y., Hyogo, H., Nakajima, T., Imajo, K., Kubotsu, Y., Isoda, H., Kawanaka, M., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4456-24 · Cited by 2
“The hypoglycemic effect of SGLT2Is improves insulin resistance, enhances gluconeogenesis, and reduces liver triglyceride synthesis (19); they improve obesity by enhancing lipolysis and may decrease skeletal muscle adipogenesis in sarcopenia (20).”
Zhang, Y., Liu, Y.-X., & Yang, W. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i1.100886 · Cited by 2
Meraj, A., & Herbert, A. (2025) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2025.143014
Abdelgani, S., Khattab, A., Adams, J. M., Al‐Mulla, F., Abu‐Farha, M., Baskoy, G., Abubaker, J. A., Merovci, A., DeFronzo, R. A., Aguiar, R. B. D., et al. (2025) · Diabetes · doi:10.2337/db25-0210
Self-citationPleiotropic Effects of Renal Disease Management: Role of SGLT2 Inhibitors
Calderón-Lojero, I. O., Valdez-Ortiz, R., & Sanchez-Pozos, K. A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305692125010018
Singh, M. P., Gupta, S., Singh, M. P., Ambrish, C., Kurmi, P. H., Gangwani, D. K., Naganna, J., Sethuraman, R., Dhumal, V., Behera, S., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03323-3 · Cited by 2
“In such cases, combination therapies, particularly those incorporating SGLT2i, have demonstrated enhanced efficacy [31–33].”
InfluentialJecht, M. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01390-2
“Ein Anstieg der Gluko-seproduktion nach der Verabreichung von SGLT2i führt jedoch dazu, dass Glukose in den systemischen Kreislauf zurückge-führt wird und die von der Niere ausge-schiedene Menge an Glukose um ~50% ausgleicht [4, 5].”
Kim, K., Ko, S., Yun, J., Lee, K. W., Kim, E., Jeong, I., Kim, J. H., Kim, S. Y., Won, K. C., Kim, M.-K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-30882-w
“Dapagliflozin improves insulin resistance in skeletal muscle 27,28 .”
Leccisotti, L., Cinti, F., Sorice, G. P., D'Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Gugliandolo, S., Cocchi, C., Capece, U., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20887485
Lyu, Y. S., Hong, S., Lee, S. E., Cho, B. Y., & Park, C.-Y. (2024) · Figshare · doi:10.6084/m9.figshare.25231187
Thirumathyam, R., Richter, E. A., van Hall, G., Holst, J. J., Fenger, M., Gøtze, J. P., Dixen, U., Vejlstrup, N., Madsbad, S., Madsen, P. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26664142
Kidoguchi, S., Kitada, K., Morishita, A., Tsuji, Y., Ohsaki, H., Yamazaki, D., Morikawa, T., Konishi, Y., Kobara, H., Yokoo, T., et al. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.12.006
The Role and Clinical Significance of miR‐484 in the Regulation of SGLT2 in Diabetic Nephropathy
Zhao, W., Sun, W., Yang, Q., Xue, L., & Wu, C. (2026) · International Journal of Endocrinology · doi:10.1155/ije/8082721
“Clinical studies indicate that SGLT2 inhibitors induce metabolic remodeling by promoting urinary glucose excretion, reducing free fatty acid (FFA) levels, and improving insulin resistance, thereby attenuating systemic and renal local infammatory responses as well as oxidative stress [18].”
Juryk, A., Król, P., Mroczka, M., Czernecka, A., Siwek, M., Dudek, D., & Jaeschke, R. R. (2026) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2025.0044
堀部, 佳., Morino, K., Miyazawa, I., Kondo, K., Sato, D., 大橋, 夏., 井田, 昌., 柳町, 剛., 吉村, 雅., 井藤, 隆., et al. (n.d.) · Institutional Repositories DataBase (IRDB)
Choi, S.-B. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.010
Legouis, D. (2020) · theses.fr (ABES) · doi:10.70675/970d29f4z1336z45e5za528z310a3cda20dd
Suciu, I. M., Muntean, C., Gaiţă, L., Mateoc-Sirb, T., Vlad, D. C., Timar, B., & Gaiță, D. I. (2026) · Biomedicines · doi:10.3390/biomedicines14040842
Étude du rôle des calpaïnes dans les complications microvasculaires du diabète
Salemkour, Y. (2023) · theses.fr (ABES) · doi:10.70675/36e8b2eezb42ez4ac4zac09z6f519c78839a
Acosta-Montalvo, A. (2022) · theses.fr (ABES) · doi:10.70675/3712a689zf56fz4ce7z814bz28dc25f0cc70
Liu, H., Zhang, Y., Feng, L., Zhang, J., Sun, Y., Zhao, Y., Jiang, M., Liu, X., Tracey, G. J., Chen, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71798-x
“This effect may be attributed to the complementary actionof dorzagliatinonglucagonregulation:Dorzagliatin has been shown to reduce glucagon secretion 10,30 , thereby counter-balancing the empagli fl ozin-induced rise in glucagon that accompanies urinary glucose excretion 27,32 .”
Xu, J., Ke, C., Qiu, Y., Chen, S., Chen, X., Bi, C., & Zhang, H. (2026) · European journal of medical research · doi:10.1186/s40001-026-04476-9
“Sodium-glucose cotransporter 2 inhibitors (SGLT-2i), for instance, improve renal and cardiovascular outcomes by enhancing urinary glucose excretion, alleviating lipotox-icity and metabolic stress, reducing inflammation and oxidative stress, and improving insulin sensitivity [48, 49].”
柏木, 厚., 荒木, 信., 前川, 聡., KASHIWAGI, A., ARAKI, S.-I., & Maegawa, H. (2020) · Institutional Repositories DataBase (IRDB)
SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review
Confederat, L. G., Pînzariu, A. C., Șerban, I. L., Condurache, M.-I., & Dragostin, O.-M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125224 · Cited by 2
“…kidney disease, two-thirds of them with diabetes and one-third without diabetes, treated with dapagliflozin versus a placebo; the results extended these renal benefits to a broader population, irrespective of diabetes status, showing a 39% reduction in the risk of the composite renal outcome [42].”
Cersósimo, E., & DeFronzo, R. A. (2026) · Kidney International · doi:10.1016/j.kint.2026.02.045
Self-citationHong, J. H. (2026) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2026.8.e9 · Cited by 1
“Several studies have shown that increased urinary glucose excretion after SGLT2 inhibition is associated with a paradoxical increase in endogenous glucose production, mainly in the liver [20,21].”
Young, M., Dambure, S., Cullen, F., Jarrah, K., McClements, L., Ramchunder, Z., & Aksentijević, D. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00119-z
“As a result, increased fatty acid mobilisation may contribute to elevated circulating lipid levels despite improved glycaemic control 19 .”
SGLT2 Inhibitors in Type 1 Diabetes: The Metabolic Perspective
Hamidi, V., & Mudaliar, S. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_825
Durma, A. C., Blicharska, M., & Czupryniak, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01913-0 · Cited by 1
“SGLT2 inhibitors also increase tissue insulin sensitivity, attenuate renal cor‑ tical inflammation and improve renal tubular oxygenation [25, 26].”
Type 2 Diabetes: Chronic Clinical Metabolic Effects of SGLT2 Inhibitors
Scheen, A. J. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_848 · Cited by 1
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals
Ferrannini, E. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_824
Takeshita, Y., Oo, H. K., Nakano, Y., Ueno, A., Oishi, M., Tsujiguchi, H., Soga, T., Yamashita, T., Honda, M., & Takamura, T. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102784
“This aligns with our previous transcriptomic data showing the upregulation of gluconeogenic genes following treatment with tofogliflozin [7], and clinical observations of increased endogenous glucose production (EGP) under SGLT2 inhibition [12,13].”
Prise en charge thérapeutique du diabète de type 2
Rigalleau, V., Cherifi, B., Blanco, L., Larroumet, A., Foussard, N., & Mohammedi, K. (2026) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(26)50825-1
John, M., Panikar, V., Seshadri, K. G., Bhartia, M., Joshi, A., PADHYE, D. A., Kapoor, N., Ayyagari, U., Periyandavar, I., Vijayakumar, G., et al. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_71_26
Habren-Syller, A.-N., & Zhurakivska, О. Y. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.6.2026.1763
Kim, D. H., Lee, M. J., Lee, S. H., Kim, J. Y., Bae, J. H., Khang, A. R., Kang, Y. H., & Yi, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219514
Svonni, E., Michanek, P., Bergsten, P., Lindåse, S. S., & Bröjer, J. T. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalag285
“18 – 20 The primar y objective of our study was therefore to determine whether short-term CAN treatment (0.4 mg /kg ) affects IS in ID horses evaluated using a euglycemic hyperinsulinemic clamp (EHC), the gold standard for measuring IS.”
Influential
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.